Monday 12 December 2016
NICE recommends dapagliflozin in triple therapy for adults with Type 2 diabetes, only in combination with metformin and a sulfonylurea.
Dapagliflozin is a selective sodium–glucose cotransporter 2 (SGLT‑2) inhibitor, which blocks the reabsorption of glucose in the kidneys and promotes excretion of excess glucose in the urine.
Dapagliflozin is being marketed in the UK for treating Type 2 diabetes to improve glycaemic control in adults:
- as monotherapy: when diet and exercise alone do not provide adequate glycaemic control in people for whom use of metformin is considered inappropriate
- in a combination therapy: with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
In addition, this new guidance has now recommended dapagliflozin in triple therapy, only in combination with metformin and a sulfonylurea. This combination of drugs will widen the choice available for people whose diabetes isn’t well controlled with two drugs and help tailor treatment to an individual’s needs.
This final guidance means that dapagliflozin joins two other similar drugs, empagliflozin and canagliflozin, as NICE-recommended options for triple therapy. All three drugs are already recommended for use on their own if a person can’t use metformin or other specific drugs, or in combination with other drugs as dual therapy.